Plain-English translation of NCT04136535 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether adding Hydrochloride to standard chemotherapy ( and ) works better than chemotherapy alone for advanced lung cancer that has become resistant to a prior drug called osimertinib. Researchers want to see if the combination helps people live longer and delays cancer growth more effectively than chemotherapy by itself.
When lung cancer stops responding to osimertinib (a targeted therapy), patients need new treatment options. This medication has shown promise in other lung cancer studies, and doctors want to find out whether combining it with standard chemotherapy could help patients whose cancer has developed resistance.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either chemotherapy plus the new medication, or chemotherapy alone. Both groups receive 4 initial cycles of chemotherapy, then those taking the new medication continue both treatments, while the other group continues chemotherapy only, until the cancer progresses or side effects become too severe. You'll have regular blood tests, scans, and doctor visits to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China